Ocular Therapeutix Inc. (NASDAQ:OCUL) stock surged on Monday after the company announced plans to accelerate the timeline for submitting a New Drug Application (NDA) for Axpaxli (OTX-TKI) in the treatment of wet age-related macular degeneration (wet AMD).The company intends to submit an NDA for Axpaxli following year one data, if positive, from its ongoing SOL-1 Phase 3 clinical trial, for which data are on track for the first quarter of 2026.William Blair noted, “Compared to prior expectations of filing af ...